iZafe Group AB (IZAFE.B) AI Stock Analysis

• Market Cap: €252.73M
• Dividend Yield: N/A
• Average Volume (3M): 1.02M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.74
• Revenue Growth: 43.22%
• EPS Growth: 47.78%
• Country: SE
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.01
• Shares Outstanding: 364,614,440
• 10 Day Avg. Volume: 1,451,881
• 30 Day Avg. Volume: 1,019,746
• PEG Ratio: 0.06
• Price to Book (P/B): 6.06
• Price to Sales (P/S): 7.41
• P/FCF Ratio: -4.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.55
• Price Target Upside: -20.51% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 45 Neutral
• Price Target: kr0.50 ▼(-27.54% Downside)

The overall stock score is primarily impacted by the company's poor financial performance and valuation. Despite strong technical momentum, the overbought conditions and lack of profitability weigh heavily on the score. The absence of earnings call insights and corporate events limits additional context for evaluation.

iZafe Group AB Business Overview & Revenue Model

Company Description

iZafe Group AB (publ), a life-science company, engages in the research, development, and marketing of digital medical solutions and services for safer drug management at home. The company provides Dosell, an automated drug dispenser that handles dose bags, facilitates and enables independent medication, and reminds and alerts if the current dose is not taken at the right time. It serves consumers, and public and private-sector care providers in Sweden, the Nordic region, and internationally. The company was formerly known as MediRätt AB (publ) and changed its name to iZafe Group AB (publ) in May 2019. iZafe Group AB (publ) was incorporated in 2008 and is headquartered in Stockholm, Sweden.

How the Company Makes Money

iZafe Group AB generates revenue through the sale of its digital health products, particularly its smart medication dispensers. The company employs a subscription-based model for its software services, allowing healthcare providers and patients to access ongoing support and updates. Additionally, iZafe may partner with healthcare facilities and organizations to implement its solutions, which can lead to revenue from service agreements and collaborations. Key revenue streams include direct product sales, subscription fees from software usage, and potential licensing agreements with third-party developers or healthcare systems.

iZafe Group AB Financial Statement Overview

Summary

iZafe Group AB faces significant financial challenges with persistent losses and negative cash flows. Despite revenue growth, the company struggles with profitability, operational efficiency, and cash management. The balance sheet shows increased leverage and a declining equity base, posing future risks.

Income Statement

The company's revenue has shown significant growth from 2023 to 2024, with a notable increase in total revenue. However, the gross profit margin remains negative, indicating costs exceed revenue, and the net profit margin is deeply negative due to substantial losses. EBIT and EBITDA margins are also negative, suggesting operational inefficiencies.

Balance Sheet

The debt-to-equity ratio has increased, indicating rising leverage, but remains moderate. The equity ratio has decreased, reflecting a decline in the proportion of assets financed by equity. Return on equity is negative due to consistent net losses, highlighting profitability challenges.

Cash Flow

Free cash flow is negative, although operating cash flow has slightly improved. The free cash flow growth rate remains negative, and the ratios of operating and free cash flow to net income are not favorable, indicating challenges in converting earnings to cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.83M	7.95M	1.82M	729.00K	442.00K	8.90M
Gross Profit	-654.00K	-1.63M	293.00K	123.00K	-1.14M	7.64M
EBITDA	-13.71M	-15.49M	-15.62M	-21.94M	-32.35M	-10.67M
Net Income	-19.14M	-20.51M	-32.17M	-23.53M	-36.27M	-12.75M
Balance Sheet
Total Assets	20.64M	24.23M	34.61M	50.70M	48.43M	35.08M
Cash, Cash Equivalents and Short-Term Investments	825.00K	2.15M	5.83M	1.70M	18.73M	2.55M
Total Debt	5.73M	6.58M	2.52M	4.00M	4.98M	750.00K
Total Liabilities	10.29M	14.50M	9.26M	11.74M	7.70M	5.62M
Stockholders Equity	10.34M	9.73M	25.35M	38.96M	40.73M	29.46M
Cash Flow
Free Cash Flow	-11.82M	-12.72M	-12.71M	-24.12M	-33.71M	-26.14M
Operating Cash Flow	-11.82M	-11.70M	-11.26M	-21.46M	-33.49M	-24.57M
Investing Cash Flow	-756.00K	-1.02M	-1.46M	-2.51M	-214.00K	19.04M
Financing Cash Flow	12.18M	8.69M	16.85M	6.94M	49.88M	604.00K

iZafe Group AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.69
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IZAFE.B, the sentiment is Positive. The current price of 0.69 is above the 20-day moving average (MA) of 0.57, above the 50-day MA of 0.45, and above the 200-day MA of 0.31, indicating a bullish trend. The MACD of 0.07 indicates Negative momentum. The RSI at 77.45 is Negative, neither overbought nor oversold. The STOCH value of 86.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IZAFE.B.

iZafe Group AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXTCL	47 Neutral	kr101.92M	―	-89.24%	―	-15.28%	36.01%
IZAFE.B	45 Neutral	€252.73M	―	-123.69%	―	43.22%	47.78%
ICO	44 Neutral	kr104.80M	―	―	―	-74.09%	26.59%
SPAGO	38 Underperform	kr86.35M	―	-90.43%	―	-16.01%	59.53%
BIOSGN	34 Underperform	kr117.41M	―	-101.53%	―	―	65.16%